Jose-manuel Carrascosa
Badalona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies: An International Real-World Study.
Journal: International journal of dermatology
Published: July 02, 2026
Narrowband UVB Phototherapy in Dermatology: 2026 Update.
Journal: Actas dermo-sifiliograficas
Published: December 03, 2025
Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial.
Journal: The Journal of dermatological treatment
Published: November 27, 2025
Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort.
Journal: Dermatology and therapy
Published: November 14, 2025
Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: October 02, 2025
Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules: BIOBADADERM registry.
Journal: The Journal of investigative dermatology
Published: June 18, 2025
Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Journal: Dermatology and therapy
Published: May 28, 2025
Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study.
Journal: Clinical and experimental dermatology
Published: May 15, 2025
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?
Journal: Dermatology and therapy
Published: April 26, 2025
Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.
Journal: Dermatology and therapy
Published: April 05, 2025
Optimizing dosing in atopic dermatitis therapy: looking for the cream of the crop.
Journal: The British journal of dermatology
Published: December 20, 2024
Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life.
Journal: Dermatology and therapy
Published: December 06, 2024
Last Updated: 09/26/2026